Skip to main content

The Board of Directors of Serengeti Energy Limited (“Serengeti”), at its meeting held on 23 February, decided on certain management changes to the company and announced that its Chief Executive Officer Dr. Chris Bale will leave the company effective 28 February 2023.

The Board has appointed Finance Director, Solomon Njonjo and Development Director, Wilfred van den Bos to the role of interim co-CEOs and has also engaged a search firm to identify the company’s next CEO to be based in the headquarters in Nairobi, Kenya. During the interim period Solomon will have the overall responsibility for existing operations, including interaction with country directors, O&M teams, finance, and general corporate services. Wilfred will have the overall responsibility for the growth part of the business, including development, project implementation and SHEC. The Board will work closely with the two co-CEOs during the transition period.

The Board would like to express its gratitude and appreciation for the work done by Dr. Chris Bale during his tenure as company CEO over the past two and a half years. Chris has been instrumental in moving Serengeti from a power development business to become a recognized renewable IPP company, including implementing structures, processes and procedures important to successful IPP operation. Under his leadership, Serengeti Energy raised additional capital of $80M from new investors, commissioned Nyamwamba II, a 7.8 MW hydro power plant in Uganda and Baoma 1, the first grid connected 5 MW solar PV power plant in Sierra Leone among other notable achievements.

“It has been a great privilege to a be part of Serengeti Energy’s growth into a leading renewable energy IPP in sub-Saharan Africa. I am confident that with the plans that have been set for the business, together with the experienced and capable team, Serengeti Energy will continue to grow it’s portfolio into a substantiable and profitable IPP.” Dr. Chris Bale remarked.

Serengeti Energy, the Board and Shareholders wish Dr. Chris Bale success in his future endeavors.